Sunrise over Sitges

Sitges – One of the noticeable things about Sitges, a former fishing village south of Barcelona, is the quality of the light. We could imagine it, like St Ives in Cornwall, as being home to artists in times past.

The sunrises and sunsets have been particularly impressive. When it comes to oncology new product development, we’re all chasing the light and the potential of a cure. That’s the promise of cancer immunotherapy.

Here at the 2nd European CAR T cell meeting, jointly organized by EHA and EBMT, we’ve heard about where we’re at with current cell therapies, some of the many challenges that have yet to be overcome and we’ve been offered insights into where some in the field are going.

2020 will be a landmark year for CAR T cell therapy with new regulatory approvals on the horizon, particularly in myeloma, but the journey to make these therapies effective in solid tumours is one where we still need to chase the light.

In this post you can read our notes and commentary on day 2 in Sitges and what caught our attention at the meeting.

To learn more from our oncology coverage and get a heads up on our latest conference analysis and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by